STOCK TITAN

Aptar Reports Third Quarter 2024 Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

AptarGroup (NYSE:ATR) reported strong Q3 2024 results with a 2% increase in both reported and core sales to $909 million. Net income rose 19% to $100 million, with earnings per share up 17% to $1.48. The Pharma segment led growth with 8% reported sales increase, while Closures grew 3% and Beauty declined 7%. The company achieved an adjusted EBITDA of $208 million, delivering a 23% margin. For Q4 2024, Aptar expects earnings per share between $1.22 and $1.30, targeting double-digit adjusted EPS growth for the full year.

AptarGroup (NYSE:ATR) ha riportato risultati solidi per il terzo trimestre 2024, con un aumento del 2% sia nelle vendite riportate che in quelle core, raggiungendo 909 milioni di dollari. Il reddito netto è aumentato del 19% fino a 100 milioni di dollari, con utili per azione in crescita del 17% a 1,48 dollari. Il segmento Pharma ha guidato la crescita con un aumento delle vendite riportate dell'8%, mentre Closures è cresciuto del 3% e Beauty ha mostrato un calo del 7%. L'azienda ha ottenuto un EBITDA rettificato di 208 milioni di dollari, con un margine del 23%. Per il quarto trimestre 2024, Aptar si aspetta utili per azione compresi tra 1,22 e 1,30 dollari, puntando a una crescita dell'EPS rettificato a due cifre per l'intero anno.

AptarGroup (NYSE:ATR) reportó resultados sólidos para el tercer trimestre de 2024, con un aumento del 2% tanto en las ventas reportadas como en las ventas principales, alcanzando los 909 millones de dólares. El ingreso neto aumentó un 19% hasta 100 millones de dólares, con ganancias por acción en aumento del 17% a 1,48 dólares. El segmento Pharma lideró el crecimiento con un incremento en las ventas reportadas del 8%, mientras que Closures creció un 3% y Beauty disminuyó un 7%. La compañía logró un EBITDA ajustado de 208 millones de dólares, ofreciendo un margen del 23%. Para el cuarto trimestre de 2024, Aptar espera que las ganancias por acción se sitúen entre 1,22 y 1,30 dólares, y busca un crecimiento de dos dígitos en el EPS ajustado para todo el año.

AptarGroup (NYSE:ATR)는 2024년 3분기에 매출이 2% 증가하여 9억 900만 달러에 도달했다고 보고했습니다. 순이익은 19% 증가하여 1억 달러에 도달하였고, 주당 순이익은 17% 상승하여 1.48달러를 기록했습니다. 제약 부문이 8%의 매출 증가로 성장을 주도하였고, 폐쇄 패키지는 3% 성장하였으며 뷰티 부문은 7% 감소했습니다. 회사는 조정된 EBITDA가 2억 800만 달러로 23%의 마진을 달성하였습니다. 2024년 4분기 동안 Aptar는 주당 순이익이 1.22달러에서 1.30달러 사이가 될 것으로 예상하며, 연간 두 자릿수의 조정된 EPS 성장을 목표로 하고 있습니다.

AptarGroup (NYSE:ATR) a annoncé des résultats solides pour le troisième trimestre 2024, avec une augmentation de 2% des ventes rapportées et des ventes de base, atteignant 909 millions de dollars. Le bénéfice net a augmenté de 19% pour atteindre 100 millions de dollars, avec un bénéfice par action en hausse de 17% à 1,48 dollar. Le segment Pharma a mené la croissance avec une augmentation des ventes rapportées de 8%, tandis que Closures a connu une croissance de 3% et Beauty a décliné de 7%. L'entreprise a réalisé un EBITDA ajusté de 208 millions de dollars, avec une marge de 23%. Pour le quatrième trimestre 2024, Aptar s'attend à un bénéfice par action compris entre 1,22 et 1,30 dollar, visant une croissance à deux chiffres de l'EPS ajusté pour l'année entière.

AptarGroup (NYSE:ATR) hat starke Ergebnisse für das dritte Quartal 2024 veröffentlicht, mit einem Anstieg von 2% sowohl bei den gemeldeten als auch bei den Kernumsätzen auf 909 Millionen US-Dollar. Der Nettogewinn stieg um 19% auf 100 Millionen US-Dollar, während der Gewinn pro Aktie um 17% auf 1,48 US-Dollar zulegte. Das Pharma-Segment führte das Wachstum mit einem Anstieg der gemeldeten Verkaufszahlen um 8%, während Closures um 3% wuchs und Beauty um 7% zurückging. Das Unternehmen erzielte ein bereinigtes EBITDA von 208 Millionen US-Dollar und erzielte eine Marge von 23%. Für das vierte Quartal 2024 erwartet Aptar einen Gewinn pro Aktie zwischen 1,22 und 1,30 US-Dollar und strebt für das gesamte Jahr ein zweistelliges Wachstum des bereinigten EPS an.

Positive
  • Net income increased 19% to $100 million
  • Pharma segment reported 8% sales growth with double-digit growth in drug delivery systems
  • Adjusted EBITDA increased 8% to $208 million with 23% margin
  • Free cash flow improved to $255 million from $124 million year-over-year
  • Net cash from operations increased to $465 million from $356 million
Negative
  • Beauty segment sales declined 7% due to lower tooling sales and unfavorable product mix
  • Chinese beauty market remains soft
  • Some customers indicated seasonal inventory right-sizing in beauty and cough & cold markets

Insights

Strong quarterly performance with $100 million net income, up 19% year-over-year. Key highlights include $909 million in sales and adjusted EBITDA of $208 million with impressive 23% margins. The Pharma segment stands out with 8% growth and 36% margins, driven by double-digit growth in drug delivery systems. Despite Beauty segment headwinds, operational improvements and cost management led to margin expansion across all segments. Free cash flow significantly improved to $255 million from $124 million. The $500 million share repurchase authorization and projected double-digit EPS growth demonstrate management's confidence in future performance.

Segment performance reveals important market dynamics: strong demand in pharmaceutical drug delivery systems, particularly in allergy, emergency medicine and CNS therapeutics. The Beauty segment faces challenges from softer Chinese market conditions and tough comparisons in prestige fragrances. Closures segment shows resilience with growing food market demand. The guidance for Q4 suggests continued momentum but acknowledges potential seasonal inventory adjustments in beauty and cough/cold markets. The successful completion of the Chinese joint venture positions Aptar strategically in a key growth market despite current headwinds.

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong third quarter results due to solid operational performance and margin improvement across the company. Results were driven by growth in proprietary drug delivery systems, as well as increased demand for closure technologies. Reported sales and core sales increased by 2%, as currency and acquisition effects did not impact the quarter. Aptar reported net income of $100 million for the quarter, a 19% increase from the prior year.

Photo: Aptar

Photo: Aptar

“Aptar delivered another strong quarter driven by our Pharma and Closures segments. We saw increased demand for our proprietary drug delivery systems, active material science solutions and closure technologies, especially for food applications. The Beauty segment saw growth in the personal care and home care markets, but it was not enough to offset tough comparisons from tooling and fragrance dispensing solutions from the prior year period. All three segments continued to demonstrate solid operational performance and margin improvement. We are proud of the strong results and progress we have made for the first nine months of the year and are positioned to achieve double-digit adjusted EPS growth for the full year,” said Stephan B. Tanda, Aptar President and CEO.

Third Quarter 2024 Highlights

  • Reported and core sales increased 2%
  • Reported earnings per share increased 17% to $1.48 and adjusted earnings per share increased 6% to $1.49
  • Reported net income of $100 million increased 19% and adjusted EBITDA increased 8% from the prior year to $208 million, delivering an adjusted EBITDA margin of 23%, which is at the high end of the long-term target range
  • Pharma segment delivered reported sales growth of 8% and core sales growth of 7% with continued demand for proprietary drug delivery systems, which grew double digits in the quarter
  • Closures segment achieved a solid quarter, with sales and margins within its long-term target ranges
  • Earlier this month, closed the previously announced joint venture transaction in China, following regulatory approvals, strengthening dispensing technology footprint

First Nine Months 2024 Highlights

  • Double-digit earnings per share growth over the prior year period
  • Net cash provided by operations increased to $465 million compared to $356 million in the prior year period
  • Free cash flow increased to $255 million compared to $124 million in the prior year

Third Quarter Results

For the quarter ended September 30, 2024, reported sales increased 2% to $909 million compared to $893 million in the prior year. Core sales, which were not impacted by currency exchange rates and acquisitions, increased 2%.

Third Quarter Segment Sales Analysis

(Change Over Prior Year)

 

Aptar

Pharma

Aptar

Beauty

Aptar

Closures

Total

AptarGroup

Reported Sales Growth

8%

(7)%

3%

2%

Currency Effects (1)

(1)%

1%

1%

0%

Acquisitions

0%

0%

0%

0%

Core Sales Growth

7%

(6)%

4%

2%

 

(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates. 

Aptar Pharma’s reported sales increased 8% from the prior year quarter and core sales were up 7%. The segment’s strong performance was driven by continued demand for proprietary drug delivery systems, which grew double digits in the quarter after growing double digits in the prior year period. Growth in the third quarter was driven by allergy, emergency medicine and central nervous system therapeutics, as well as growing royalty revenues, boosting margins to 36%, which is at the top end of the long-term range. The Active Material Science division also grew double digits, with demand increasing across a number of end markets.

Aptar Beauty’s reported sales decreased 7%, and including currency effects core sales were down 6% compared to the prior year quarter. Approximately 4% of the decline in core sales can be attributed to lower tooling sales, with less favorable product mix contributing the remaining 2% of the decline. While revenue increased from the personal care and home care markets, this increase could not offset the challenging comparisons from prestige fragrance sales in the prior year period. Sales in North America improved progressively, while the Chinese beauty market remains soft. Margins were up year over year for Beauty, with improved operational performance and cost management remaining important points of focus for the segment.

Aptar Closures’ reported sales increased 3% from the prior year quarter and the segment’s core sales increased 4%. The increase in core sales was driven mainly by demand for closures in the food end market. Closures delivered a solid quarter and was within its long-term target ranges for both core sales and adjusted EBITDA margins. The segment’s margins increased by nearly 200 basis points over the prior year quarter, due to increased plant utilization and ongoing cost containment efforts.

Aptar reported third quarter earnings per share of $1.48, an increase of 17%, compared to $1.26 during the same period a year ago. Third quarter adjusted earnings per share, excluding restructuring charges and the unrealized gains or losses on an equity investment, were $1.49, an increase of 6%, compared to $1.40 in the prior year, including comparable exchange rates. The third quarter had an effective tax rate of 24% compared to the prior year period effective tax rate of 23%.

Year-To-Date Results

For the nine months ended September 30, 2024, reported sales increased 3% to $2.73 billion compared to $2.65 billion in the prior year. Core sales, which were not impacted by currency exchange rates and acquisitions, also increased 3%.

Nine Months Year-To-Date Segment Sales Analysis

(Change Over Prior Year)

 

Aptar

Pharma

Aptar

Beauty

Aptar

Closures

Total

AptarGroup

Total Reported Sales Growth

9%

(3)%

1%

3%

Currency Effects (1)

0%

0%

1%

0%

Acquisitions

0%

0%

0%

0%

Core Sales Growth

9%

(3)%

2%

3%

 

(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates. 

For the nine months ended September 30, 2024, Aptar’s reported earnings per share were $4.05, an increase of 22%, compared to $3.32 reported a year ago. Current year adjusted earnings per share, excluding restructuring charges, acquisition costs, and the unrealized gains or losses on an equity investment, were $4.12 and increased 15% from prior year adjusted earnings per share of $3.58, including comparable exchange rates. The current year had an effective tax rate of 23% comparable to the prior year period effective tax rate of 25%.

Outlook

Regarding Aptar’s outlook, Tanda stated, “Looking to the fourth quarter, we anticipate a solid finish to a strong year. The top line is expected to grow in the fourth quarter, even with some customers having indicated seasonal inventory right-sizing in the beauty and cough & cold end markets. Our pharma business should finish full year 2024 within its core sales long-term target range of 7-11%, driven by demand for allergy medication, emergency medicine and central nervous system therapies. The segment will deliver solid, double-digit adjusted EBITDA growth in 2024 due in part to sales of higher value products and royalties. Our Closures segment has returned to growth and we expect a strong finish to 2024, with healthy adjusted EBITDA margin improvements over the prior year. Beauty is battling a tough macro environment but continues to focus on the bottom line. Innovation, cost mitigation, improved operational leverage and accelerating efficiencies remain key priorities for our teams.”

Aptar currently expects earnings per share for the fourth quarter of 2024, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $1.22 to $1.30. This guidance is based on an effective tax rate range of 20% to 22% with a comparable adjusted prior year effective tax rate of 24%. The earnings per share guidance range is based on spot rates at the end of September for all currencies. Based on the fourth quarter guidance, full year adjusted EPS would be in the range of $5.34 to $5.42, a double-digit increase over full year 2023.

Share Repurchase Authorization and Cash Dividend

As previously reported, Aptar’s Board of Directors authorized the repurchase of $500 million of the Company’s common stock. This new authorization replaces all previous authorizations. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. The Board also approved the quarterly cash dividend of $0.45 per share. The payment date is November 14, 2024, to stockholders of record as of October 24, 2024. During the third quarter, Aptar repurchased 95 thousand shares for approximately $14 million.

Open Conference Call

There will be a conference call held on Friday, October 25, 2024 at 8:00 a.m. Central Time to discuss the company’s third quarter results for 2024. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investor Relations website at investors.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investor Relations page of the website.

About Aptar

Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has more than 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

Presentation of Non-GAAP Information

This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of restructuring initiatives, acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments and net unrealized investment gains and losses related to observable market price changes on equity securities. Core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Adjusted EBITDA margin is adjusted EBITDA divided by reported net sales. Non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar’s management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect Aptar’s core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar’s management when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of the company's routine activities, such as restructuring and acquisition costs.

This press release contains forward-looking statements, including certain statements set forth under the “Outlook” section of this press release. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: geopolitical conflicts worldwide including the invasion of Ukraine by the Russian military and the recent events in the Middle East and the resulting indirect impact on demand from our customers selling their products into these countries, as well as rising input costs and certain supply chain disruptions; the availability of raw materials and components (particularly from sole sourced suppliers for some of our Pharma solutions) as well as the financial viability of these suppliers; lower demand and asset utilization due to an economic recession either globally or in key markets we operate within; economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth; the execution of our fixed cost reduction initiatives, including our optimization initiative; fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs (particularly resin, metal, anodization costs and energy costs); significant fluctuations in foreign currency exchange rates or our effective tax rate; the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; changes in customer and/or consumer spending levels; loss of one or more key accounts; our ability to successfully implement facility expansions and new facility projects; our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases; changes in capital availability or cost, including rising interest rates; volatility of global credit markets; our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired, including contingent consideration valuation; our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio; direct or indirect consequences of acts of war, terrorism or social unrest; cybersecurity threats against our systems and/or service providers that could impact our networks and reporting systems; the impact of natural disasters and other weather-related occurrences; fiscal and monetary policies and other regulations; changes, difficulties or failures in complying with government regulation, including FDA or similar foreign governmental authorities; changing regulations or market conditions regarding environmental sustainability; work stoppages due to labor disputes; competition, including technological advances; our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights; the outcome of any legal proceeding that has been or may be instituted against us and others; our ability to meet future cash flow estimates to support our goodwill impairment testing; the demand for existing and new products; the success of our customers’ products, particularly in the pharmaceutical industry; our ability to manage worldwide customer launches of complex technical products, particularly in developing markets; difficulties in product development and uncertainties related to the timing or outcome of product development; significant product liability claims; and other risks associated with our operations. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 
 
 

AptarGroup, Inc.
Condensed Consolidated Financial Statements (Unaudited)
(In Thousands, Except Per Share Data)
Consolidated Statements of Income 

 

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

 

 

 

 

 

 

 

 

Net Sales

$

909,291

 

 

$

892,997

 

 

$

2,734,802

 

 

$

2,648,970

 

Cost of Sales (exclusive of depreciation and amortization shown below)

 

558,511

 

 

 

566,691

 

 

 

1,708,707

 

 

 

1,697,824

 

Selling, Research & Development and Administrative

 

141,604

 

 

 

138,137

 

 

 

443,714

 

 

 

427,488

 

Depreciation and Amortization

 

67,015

 

 

 

62,686

 

 

 

196,332

 

 

 

184,212

 

Restructuring Initiatives

 

3,864

 

 

 

6,161

 

 

 

9,659

 

 

 

19,628

 

Operating Income

 

138,297

 

 

 

119,322

 

 

 

376,390

 

 

 

319,818

 

Other Income (Expense):

 

 

 

 

 

 

 

Interest Expense

 

(12,290

)

 

 

(9,984

)

 

 

(32,526

)

 

 

(29,900

)

Interest Income

 

3,022

 

 

 

946

 

 

 

9,022

 

 

 

2,266

 

Net Investment Gain (Loss)

 

1,043

 

 

 

(1,240

)

 

 

1,495

 

 

 

1,839

 

Equity in Results of Affiliates

 

(77

)

 

 

1,002

 

 

 

(168

)

 

 

1,514

 

Miscellaneous Income (Expense), net

 

1,136

 

 

 

3

 

 

 

(518

)

 

 

(1,341

)

Income before Income Taxes

 

131,131

 

 

 

110,049

 

 

 

353,695

 

 

 

294,196

 

Provision for Income Taxes

 

31,209

 

 

 

25,751

 

 

 

80,382

 

 

 

72,265

 

Net Income

$

99,922

 

 

$

84,298

 

 

$

273,313

 

 

$

221,931

 

Net Loss (Gain) Attributable to Noncontrolling Interests

 

117

 

 

 

(2

)

 

 

284

 

 

 

201

 

Net Income Attributable to AptarGroup, Inc.

$

100,039

 

 

$

84,296

 

 

$

273,597

 

 

$

222,132

 

Net Income Attributable to AptarGroup, Inc. per Common Share:

 

 

 

 

 

 

 

Basic

$

1.51

 

 

$

1.28

 

 

$

4.13

 

 

$

3.39

 

Diluted

$

1.48

 

 

$

1.26

 

 

$

4.05

 

 

$

3.32

 

 

 

 

 

 

 

 

 

Average Numbers of Shares Outstanding:

 

 

 

 

 

 

 

Basic

 

66,445

 

 

 

65,707

 

 

 

66,274

 

 

 

65,550

 

Diluted

 

67,716

 

 

 

67,035

 

 

 

67,574

 

 

 

66,865

 

   
   
   
   

AptarGroup, Inc.
Condensed Consolidated Financial Statements (Unaudited)
(continued)
($ In Thousands)
Consolidated Balance Sheets

   

 

September 30,

024

 

December 31,

2023

ASSETS

 

 

 

 

 

 

 

 

 

 

 

Cash and Equivalents

$

325,524

 

 

$

223,643

 

Short-term Investments

 

2,387

 

 

 

 

Accounts and Notes Receivable, Net

 

698,989

 

 

 

677,822

 

Inventories

 

488,540

 

 

 

513,053

 

Prepaid and Other

 

150,164

 

 

 

134,761

 

Total Current Assets

 

1,665,604

 

 

 

1,549,279

 

Property, Plant and Equipment, Net

 

1,505,209

 

 

 

1,478,063

 

Goodwill

 

968,293

 

 

 

963,418

 

Other Assets

 

486,109

 

 

 

461,130

 

Total Assets

$

4,625,215

 

 

$

4,451,890

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

 

 

Short-Term Obligations

$

253,112

 

 

$

458,220

 

Accounts Payable, Accrued and Other Liabilities

 

773,540

 

 

 

793,089

 

Total Current Liabilities

 

1,026,652

 

 

 

1,251,309

 

Long-Term Obligations

 

822,731

 

 

 

681,188

 

Deferred Liabilities and Other

 

222,191

 

 

 

198,095

 

Total Liabilities

 

2,071,574

 

 

 

2,130,592

 

 

 

 

 

 

 

AptarGroup, Inc. Stockholders' Equity

 

2,539,009

 

 

 

2,306,824

 

Noncontrolling Interests in Subsidiaries

 

14,632

 

 

 

14,474

 

Total Stockholders' Equity

 

2,553,641

 

 

 

2,321,298

 

 

 

 

 

 

 

Total Liabilities and Stockholders' Equity

$

4,625,215

 

 

$

4,451,890

 
 
 
 
 

AptarGroup, Inc.
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)
($ In Thousands) 

 

 

Three Months Ended

September 30, 2024

 

 

 

Consolidated

 

 

Aptar Pharma

 

Aptar Beauty

 

Aptar Closures

 

Corporate

& Other

 

Net Interest

Net Sales

$

909,291

 

 

 

$

420,594

 

 

$

302,859

 

 

$

185,838

 

 

$

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported net income

$

99,922

 

 

 

 

 

 

 

 

 

 

 

 

Reported income taxes

 

31,209

 

 

 

 

 

 

 

 

 

 

 

 

Reported income before income taxes

 

131,131

 

 

 

 

120,243

 

 

 

17,839

 

 

 

18,042

 

 

 

(15,725

)

 

 

(9,268

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring initiatives

 

3,864

 

 

 

 

564

 

 

 

1,962

 

 

 

877

 

 

 

461

 

 

 

Curtailment gain related to restructuring initiatives

 

(1,851

)

 

 

 

 

 

 

 

 

 

(1,851

)

 

 

 

 

 

Net investment gain

 

(1,043

)

 

 

 

 

 

 

 

 

 

 

 

 

(1,043

)

 

 

Adjusted earnings before income taxes

 

132,101

 

 

 

 

120,807

 

 

 

19,801

 

 

 

17,068

 

 

 

(16,307

)

 

 

(9,268

)

Interest expense

 

12,290

 

 

 

 

 

 

 

 

 

 

 

 

12,290

 

Interest income

 

(3,022

)

 

 

 

 

 

 

 

 

 

 

 

(3,022

)

Adjusted earnings before net interest and taxes (Adjusted EBIT)

 

141,369

 

 

 

 

120,807

 

 

 

19,801

 

 

 

17,068

 

 

 

(16,307

)

 

 

 

Depreciation and amortization

 

67,015

 

 

 

 

30,787

 

 

 

20,420

 

 

 

14,912

 

 

 

896

 

 

 

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)

$

208,384

 

 

 

$

151,594

 

 

$

40,221

 

 

$

31,980

 

 

$

(15,411

)

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported net income margins (Reported net income / Reported Net Sales)

 

11.0

%

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)

 

22.9

%

 

 

 

36.0

%

 

 

13.3

%

 

 

17.2

%

 

 

 

 

 

 

Three Months Ended

September 30, 2023

 

 

 

Consolidated

 

 

Aptar Pharma

 

Aptar Beauty

 

Aptar Closures

 

Corporate

& Other

 

Net Interest

Net Sales

$

892,997

 

 

 

$

389,188

 

 

$

323,980

 

 

$

179,829

 

 

$

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported net income

$

84,298

 

 

 

 

 

 

 

 

 

 

 

 

Reported income taxes

 

25,751

 

 

 

 

 

 

 

 

 

 

 

 

Reported income before income taxes

 

110,049

 

 

 

 

108,113

 

 

 

17,415

 

 

 

11,647

 

 

 

(18,088

)

 

 

(9,038

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring initiatives

 

6,161

 

 

 

 

92

 

 

 

2,880

 

 

 

3,098

 

 

 

91

 

 

 

Net investment loss

 

1,240

 

 

 

 

 

 

 

 

 

 

 

 

 

1,240

 

 

 

Realized gain on investments included in net investment loss above

 

4,188

 

 

 

 

 

 

 

 

 

 

 

 

 

4,188

 

 

 

Adjusted earnings before income taxes

 

121,638

 

 

 

 

108,205

 

 

 

20,295

 

 

 

14,745

 

 

 

(12,569

)

 

 

(9,038

)

Interest expense

 

9,984

 

 

 

 

 

 

 

 

 

 

 

 

9,984

 

Interest income

 

(946

)

 

 

 

 

 

 

 

 

 

 

 

(946

)

Adjusted earnings before net interest and taxes (Adjusted EBIT)

 

130,676

 

 

 

 

108,205

 

 

 

20,295

 

 

 

14,745

 

 

 

(12,569

)

 

 

 

Depreciation and amortization

 

62,686

 

 

 

 

28,139

 

 

 

20,775

 

 

 

12,862

 

 

 

910

 

 

 

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)

$

193,362

 

 

 

$

136,344

 

 

$

41,070

 

 

$

27,607

 

 

$

(11,659

)

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported net income margins (Reported net income / Reported Net Sales)

 

9.4

%

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)

 

21.7

%

 

 

 

35.0

%

 

 

12.7

%

 

 

15.4

%

 

 

 

 

 
 
 
 

AptarGroup, Inc.
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)
($ In Thousands) 

 

 

Nine Months Ended

September 30, 2024

 

 

 

Consolidated

 

 

Aptar Pharma

 

Aptar Beauty

 

Aptar Closures

 

Corporate

& Other

 

Net Interest

Net Sales

$

2,734,802

 

 

 

$

1,242,420

 

 

$

951,666

 

 

$

540,716

 

 

$

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported net income

$

273,313

 

 

 

 

 

 

 

 

 

 

 

 

Reported income taxes

 

80,382

 

 

 

 

 

 

 

 

 

 

 

 

Reported income before income taxes

 

353,695

 

 

 

 

335,409

 

 

 

57,808

 

 

 

42,883

 

 

 

(58,901

)

 

 

(23,504

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring initiatives

 

9,659

 

 

 

 

653

 

 

 

5,871

 

 

 

2,530

 

 

 

605

 

 

 

Curtailment gain related to restructuring initiatives

 

(1,851

)

 

 

 

 

 

 

 

 

 

(1,851

)

 

 

 

 

 

Net investment gain

 

(1,495

)

 

 

 

 

 

 

 

 

 

 

 

 

(1,495

)

 

 

Transaction costs related to acquisitions

 

140

 

 

 

 

 

 

 

140

 

 

 

 

 

 

 

 

 

Adjusted earnings before income taxes

 

360,148

 

 

 

 

336,062

 

 

 

63,819

 

 

 

43,562

 

 

 

(59,791

)

 

 

(23,504

)

Interest expense

 

32,526

 

 

 

 

 

 

 

 

 

 

 

 

32,526

 

Interest income

 

(9,022

)

 

 

 

 

 

 

 

 

 

 

 

(9,022

)

Adjusted earnings before net interest and taxes (Adjusted EBIT)

 

383,652

 

 

 

 

336,062

 

 

 

63,819

 

 

 

43,562

 

 

 

(59,791

)

 

 

 

Depreciation and amortization

 

196,332

 

 

 

 

89,198

 

 

 

62,174

 

 

 

42,697

 

 

 

2,263

 

 

 

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)

$

579,984

 

 

 

$

425,260

 

 

$

125,993

 

 

$

86,259

 

 

$

(57,528

)

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported net income margins (Reported net income / Reported Net Sales)

 

10.0

%

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)

 

21.2

%

 

 

 

34.2

%

 

 

13.2

%

 

 

16.0

%

 

 

 

 

 

 

Nine Months Ended

September 30, 2023

 

 

 

Consolidated

 

 

Aptar Pharma

 

Aptar Beauty

 

Aptar Closures

 

Corporate

& Other

 

Net Interest

Net Sales

$

2,648,970

 

 

 

$

1,135,934

 

 

$

979,956

 

 

$

533,080

 

 

$

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported net income

$

221,931

 

 

 

 

 

 

 

 

 

 

 

 

Reported income taxes

 

72,265

 

 

 

 

 

 

 

 

 

 

 

 

Reported income before income taxes

 

294,196

 

 

 

 

288,603

 

 

 

46,643

 

 

 

39,174

 

 

 

(52,590

)

 

 

(27,634

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring initiatives

 

19,628

 

 

 

 

1,657

 

 

 

12,650

 

 

 

4,060

 

 

 

1,261

 

 

 

Net investment gain

 

(1,839

)

 

 

 

 

 

 

 

 

 

 

 

 

(1,839

)

 

 

Realized gain on investments included in net investment gain above

 

4,188

 

 

 

 

 

 

 

 

 

 

 

 

 

4,188

 

 

 

Transaction costs related to acquisitions

 

255

 

 

 

 

 

 

 

199

 

 

 

56

 

 

 

 

 

 

Adjusted earnings before income taxes

 

316,428

 

 

 

 

290,260

 

 

 

59,492

 

 

 

43,290

 

 

 

(48,980

)

 

 

(27,634

)

Interest expense

 

29,900

 

 

 

 

 

 

 

 

 

 

 

 

29,900

 

Interest income

 

(2,266

)

 

 

 

 

 

 

 

 

 

 

 

(2,266

)

Adjusted earnings before net interest and taxes (Adjusted EBIT)

 

344,062

 

 

 

 

290,260

 

 

 

59,492

 

 

 

43,290

 

 

 

(48,980

)

 

 

 

Depreciation and amortization

 

184,212

 

 

 

 

81,248

 

 

 

61,883

 

 

 

38,097

 

 

 

2,984

 

 

 

 

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)

$

528,274

 

 

 

$

371,508

 

 

$

121,375

 

 

$

81,387

 

 

$

(45,996

)

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported net income margins (Reported net income / Reported Net Sales)

 

8.4

%

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)

 

19.9

%

 

 

 

32.7

%

 

 

12.4

%

 

 

15.3

%

 

 

 

 

 
 
 
 

AptarGroup, Inc.
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)
(In Thousands, Except Per Share Data) 

 

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

 

 

 

 

 

 

 

 

Income before Income Taxes

$

131,131

 

 

$

110,049

 

 

$

353,695

 

 

$

294,196

 

 

 

 

 

 

 

 

 

Adjustments:

 

 

 

 

 

 

 

Restructuring initiatives

 

3,864

 

 

 

6,161

 

 

 

9,659

 

 

 

19,628

 

Curtailment gain related to restructuring initiatives

 

(1,851

)

 

 

 

 

 

(1,851

)

 

 

 

Net investment (gain) loss

 

(1,043

)

 

 

1,240

 

 

 

(1,495

)

 

 

(1,839

)

Realized gain on investments included in net investment (gain) loss above

 

 

 

 

4,188

 

 

 

 

 

 

4,188

 

Transaction costs related to acquisitions

 

 

 

 

 

 

 

140

 

 

 

255

 

Foreign currency effects (1)

 

 

 

1,261

 

 

 

 

 

1,491

 

Adjusted Earnings before Income Taxes

$

132,101

 

 

$

122,899

 

 

$

360,148

 

 

$

317,919

 

 

 

 

 

 

 

 

 

Provision for Income Taxes

$

31,209

 

 

$

25,751

 

 

$

80,382

 

 

$

72,265

 

 

 

 

 

 

 

 

 

Adjustments:

 

 

 

 

 

 

 

Restructuring initiatives

 

1,013

 

 

 

1,611

 

 

 

2,471

 

 

 

5,170

 

Curtailment gain related to restructuring initiatives

 

(478

)

 

 

 

 

 

(478

)

 

 

 

Net investment (gain) loss

 

(255

)

 

 

304

 

 

 

(366

)

 

 

(450

)

Realized gain on investments included in net investment (gain) loss above

 

 

 

 

1,026

 

 

 

 

 

 

1,026

 

Transaction costs related to acquisitions

 

 

 

 

 

 

 

35

 

 

 

65

 

Foreign currency effects (1)

 

 

 

295

 

 

 

 

 

366

 

Adjusted Provision for Income Taxes

$

31,489

 

 

$

28,987

 

 

$

82,044

 

 

$

78,442

 

 

 

 

 

 

 

 

 

Net Loss (Income) Attributable to Noncontrolling Interests

$

117

 

 

$

(2

)

 

$

284

 

 

$

201

 

 

 

 

 

 

 

 

 

Net Income Attributable to AptarGroup, Inc.

$

100,039

 

 

$

84,296

 

 

$

273,597

 

 

$

222,132

 

 

 

 

 

 

 

 

 

Adjustments:

 

 

 

 

 

 

 

Restructuring initiatives

 

2,851

 

 

 

4,550

 

 

 

7,188

 

 

 

14,458

 

Curtailment gain related to restructuring initiatives

 

(1,373

)

 

 

 

 

 

(1,373

)

 

 

 

Net investment (gain) loss

 

(788

)

 

 

936

 

 

 

(1,129

)

 

 

(1,389

)

Realized gain on investments included in net investment (gain) loss above

 

 

 

 

3,162

 

 

 

 

 

 

3,162

 

Transaction costs related to acquisitions

 

 

 

 

 

 

 

105

 

 

 

190

 

Foreign currency effects (1)

 

 

 

966

 

 

 

 

 

1,125

 

Adjusted Net Income Attributable to AptarGroup, Inc.

$

100,729

 

 

$

93,910

 

 

$

278,388

 

 

$

239,678

 

 

 

 

 

 

 

 

 

Average Number of Diluted Shares Outstanding

 

67,716

 

 

 

67,035

 

 

 

67,574

 

 

 

66,865

 

 

 

 

 

 

 

 

 

Net Income Attributable to AptarGroup, Inc. Per Diluted Share

$

1.48

 

 

$

1.26

 

 

$

4.05

 

 

$

3.32

 

 

 

 

 

 

 

 

 

Adjustments:

 

 

 

 

 

 

 

Restructuring initiatives

 

0.04

 

 

 

0.07

 

 

 

0.11

 

 

 

0.22

 

Curtailment gain related to restructuring initiatives

 

(0.02

)

 

 

 

 

 

(0.02

)

 

 

 

Net investment (gain) loss

 

(0.01

)

 

 

0.01

 

 

 

(0.02

)

 

 

(0.02

)

Realized gain on investments included in net investment (gain) loss above

 

 

 

 

0.05

 

 

 

 

 

 

0.05

 

Transaction costs related to acquisitions

 

 

 

 

 

 

 

 

 

 

 

Foreign currency effects (1)

 

 

 

0.01

 

 

 

 

 

0.01

 

Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share

$

1.49

 

 

$

1.40

 

 

$

4.12

 

 

$

3.58

 

 

(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current period foreign currency exchange rates. 

 
 
 
 

AptarGroup, Inc.
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited)
(In Thousands) 

 

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

 

 

 

 

 

 

 

 

Net Cash Provided by Operations

$

229,262

 

 

$

173,401

 

 

$

465,174

 

 

$

355,602

 

Capital Expenditures

 

(66,550

)

 

 

(76,187

)

 

 

(210,416

)

 

 

(231,199

)

Free Cash Flow

$

162,712

 

 

$

97,214

 

 

$

254,758

 

 

$

124,403

 

   
   
   
   

AptarGroup, Inc.
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)
(In Thousands, Except Per Share Data)

   

 

Three Months Ending

December 31,

 

Expected 2024

 

2023

 

 

 

 

 

Income before Income Taxes

 

 

$

80,629

 

 

 

 

 

 

Adjustments:

 

 

 

 

Restructuring initiatives

 

 

 

25,376

 

Net investment loss

 

 

 

426

 

Transaction costs related to acquisitions

 

 

 

225

 

Foreign currency effects (1)

 

 

 

2,206

 

Adjusted Earnings before Income Taxes

 

 

$

108,862

 

 

 

 

 

 

Provision for Income Taxes

 

 

$

18,384

 

 

 

 

 

 

Adjustments:

 

 

 

 

Restructuring initiatives

 

 

 

6,769

 

Net investment loss

 

 

 

104

 

Transaction costs related to acquisitions

 

 

 

56

 

Foreign currency effects (1)

 

 

 

503

 

Adjusted Provision for Income Taxes

 

 

$

25,816

 

 

 

 

 

 

Net Loss Attributable to Noncontrolling Interests

 

 

$

110

 

 

 

 

 

 

Net Income Attributable to AptarGroup, Inc.

 

 

$

62,355

 

 

 

 

 

 

Adjustments:

 

 

 

 

Restructuring initiatives

 

 

 

18,607

 

Net investment loss

 

 

 

322

 

Transaction costs related to acquisitions

 

 

 

169

 

Foreign currency effects (1)

 

 

 

1,703

 

Adjusted Net Income Attributable to AptarGroup, Inc.

 

 

$

83,156

 

 

 

 

 

 

Average Number of Diluted Shares Outstanding

 

 

 

67,131

 

 

 

 

 

 

Net Income Attributable to AptarGroup, Inc. Per Diluted Share (3)

 

 

$

0.93

 

 

 

 

 

 

Adjustments:

 

 

 

 

Restructuring initiatives

 

 

 

0.28

 

Net investment loss

 

 

 

 

Transaction costs related to acquisitions

 

 

 

 

Foreign currency effects (1)

 

 

 

0.03

 

Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share (2)

$1.22 - $1.30

 

$

1.24

 
   

(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using spot rates as of September 30, 2024 for all applicable foreign currency exchange rates.

   

(2) AptarGroup’s expected earnings per share range for the fourth quarter of 2024, excluding any restructuring expenses, acquisition costs and changes in fair value of equity investments, is based on an effective tax rate range of 20% to 22%. This tax rate range compares to our fourth quarter of 2023 effective tax rate of 23% on reported earnings per share and 24% on adjusted earnings per share.

   
   

 

Investor Relations Contact:

Mary Skafidas

mary.skafidas@aptar.com

815-479-5530

Media Contact:

Katie Reardon

katie.reardon@aptar.com

815-479-5671

Source: AptarGroup, Inc.

FAQ

What was AptarGroup's (ATR) revenue growth in Q3 2024?

AptarGroup reported a 2% increase in both reported and core sales to $909 million in Q3 2024.

How much did ATR's Pharma segment grow in Q3 2024?

Aptar's Pharma segment reported 8% sales growth and 7% core sales growth in Q3 2024.

What is ATR's Q4 2024 earnings guidance?

Aptar expects Q4 2024 earnings per share to be between $1.22 and $1.30, excluding restructuring expenses and other costs.

What was ATR's net income in Q3 2024?

AptarGroup reported net income of $100 million in Q3 2024, a 19% increase from the prior year.

AptarGroup, Inc.

NYSE:ATR

ATR Rankings

ATR Latest News

ATR Stock Data

11.26B
66.08M
0.56%
92.35%
0.68%
Medical Instruments & Supplies
Plastics Products, Nec
Link
United States of America
CRYSTAL LAKE